In recent years, drug reformulation has emerged as a popular defence strategy among pharmaceutical companies seeking to prolong the life cycles of their best-selling products. It has also attracted gr
Privately held Kotinos Pharmaceuticals has agreed to buy Ambrilia Biopharma's prostate cancer therapeutic PCK3145 and related assets for up to $15 million. Ambrilia will receive $200,000 upfront in th